<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-2V11WQ2W</identifier><date>2019</date><creator>Škof, Erik</creator><relation>documents/doc/2/URN_NBN_SI_doc-2V11WQ2W_001.pdf</relation><relation>documents/doc/2/URN_NBN_SI_doc-2V11WQ2W_001.txt</relation><format format_type="extent">66 str., 21 cm</format><identifier identifier_type="COBISSID_HOST">3175803</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-2V11WQ2W</identifier><language>slv</language><publisher>Onkološki inštitut</publisher><source>knjige</source><rights>InC</rights><subject language_type_id="slv">Bolezni</subject><subject language_type_id="slv">BRCA</subject><subject language_type_id="eng">disease</subject><subject language_type_id="slv">gen dovzetnosti za pojav raka dojk</subject><subject language_type_id="slv">Jajčnik</subject><subject language_type_id="slv">Kemoterapija</subject><subject language_type_id="slv">olaparib</subject><subject language_type_id="slv">Rak (medicina)</subject><subject language_type_id="slv">rak jajčnikov</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="slv">zaviralci PARP</subject><subject language_type_id="slv">Zdravljenje</subject><title>Olaparib za zdravljenje raka jajčnikov</title></Record>